Sugi Predict

Sugi Predict / Compounds / SCHEMBL29394906

SCHEMBL29394906

SCHEMBL29394906

CCCC[C@H](N)C(=O)NC(Cc1ccc(O)cc1)C(=O)N[C@H](CN[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O)CC(C)C

nearest known ligand 0.79

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ REN P00797 13/20 0.79
▸ AGTR1 P30556 1/20 0.62
▸ AGTR2 P50052 1/20 0.62
▸ LNPEP Q9UIQ6 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24849923 0.85 REN (0.78) RENAGTR1AGTR2LNPEP
SCHEMBL29934365 0.84 AGTR2 (0.77) RENAGTR1AGTR2
SCHEMBL30305967 0.83 REN (0.92) RENAGTR1AGTR2LNPEP
SCHEMBL29619763 0.81 AGTR1 (0.75) RENAGTR1AGTR2LNPEP
SCHEMBL31332289 0.81 AGTR2 (0.91) RENAGTR1AGTR2LNPEP
SCHEMBL13234128 0.80 AGTR1 (0.69) RENAGTR1AGTR2LNPEP
Angiotensin Iv SCHEMBL27169570 0.80 LNPEP (0.82) RENAGTR1AGTR2LNPEP
Angiotensin Iv SCHEMBL10066237 0.80 LNPEP (0.82) RENAGTR1AGTR2LNPEP
Angiotensin Amide SCHEMBL8155919 0.79 AGTR2 (0.74) RENAGTR1AGTR2LNPEP
Angiotensin Amide SCHEMBL9324 0.79 AGTR2 (0.74) RENAGTR1AGTR2LNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398146-A1 IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT SURGE Therapeutics, Inc. 2023-12-14 — — US disclosed
EP-4196122-A1 IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT Surge Therapeutics, Inc. (US) 2023-06-21 — — EP disclosed
WO-2022040246-A1 IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT STIMIT CORPORATION (US) 2022-02-24 — — WO disclosed
Send feedback